The Challenges and Prospects of p53-Based Therapies in Ovarian Cancer.
The Challenges and Prospects of p53-Based Therapies in Ovarian Cancer.
复制标题
DOI：
10.3390/biom13010159
复制
发表时间：
2023-01-12
期刊：
影响因子：
5.5
通讯作者：
中科院分区：
文献类型：
--
作者：
肿瘤抑制基因p53的突变在绝大多数癌症肿瘤中容易发生，包括卵巢癌。卵巢癌通常在第三或第四阶段被诊断出来，是女性死亡的第五大原因，尽管仅占所有女性恶性肿瘤的2.5%。卵巢癌的总体5年生存率约为47%;然而，对于最常见的卵巢癌类型，高级别浆液性卵巢癌（HGSOC），这一生存率下降至29%。HGSOC有超过96%的病例表达p53突变。因此，野生型（WT）p53和基于p53的疗法已被探索为通过过多的药物递送载体（包括纳米颗粒、病毒、聚合物和脂质体）的治疗选择。然而，先前的p53治疗剂面临许多挑战，这导致其迄今为止有限的翻译成功。这篇综述重点介绍了这些历史性的p53靶向治疗卵巢癌的方法，它们失败的原因，以及新一代此类治疗方法的未来。
It has been well established that mutations in the tumor suppressor gene, p53, occur readily in a vast majority of cancer tumors, including ovarian cancer. Typically diagnosed in stages three or four, ovarian cancer is the fifth leading cause of death in women, despite accounting for only 2.5% of all female malignancies. The overall 5-year survival rate for ovarian cancer is around 47%; however, this drops to an abysmal 29% for the most common type of ovarian cancer, high-grade serous ovarian carcinoma (HGSOC). HGSOC has upwards of 96% of cases expressing mutations in p53. Therefore, wild-type (WT) p53 and p53-based therapies have been explored as treatment options via a plethora of drug delivery vehicles including nanoparticles, viruses, polymers, and liposomes. However, previous p53 therapeutics have faced many challenges, which have resulted in their limited translational success to date. This review highlights a selection of these historical p53-targeted therapeutics for ovarian cancer, why they failed, and what the future could hold for a new generation of this class of therapies.
登录
查看更多内容
影响因子：
7.3
作者：
Ahmed, Ashour Ahmed;Etemadmoghadam, Dariush;Temple, Jillian;Lynch, Andy G.;Riad, Mohamed;Sharma, Raghwa;Stewart, Colin;Fereday, Sian;Caldas, Carlos;DeFazio, Anna;Bowtell, David;Brenton, James D.
通讯作者：
Brenton, James D.
影响因子：
3.7
作者：
Wojnarowicz PM;Oros KK;Quinn MC;Arcand SL;Gambaro K;Madore J;Birch AH;de Ladurantaye M;Rahimi K;Provencher DM;Mes-Masson AM;Greenwood CM;Tonin PN
通讯作者：
Tonin PN
DOI：
10.1038/nrc2644
发表时间：
2009-06
期刊：
Nature reviews. Cancer
影响因子：
--
作者：
通讯作者：
--
影响因子：
2.7
作者：
Gamble LJ;Borovjagin AV;Matthews QL
通讯作者：
Matthews QL
影响因子：
2.9
作者：
Chen S;Cavazza E;Barlier C;Salleron J;Filhine-Tresarrieu P;Gavoilles C;Merlin JL;Harlé A
通讯作者：
Harlé A